Jimmie Harvey
Directeur/Membre du Conseil chez FORTRESS BIOTECH, INC.
Fortune : 120 398 $ au 30/04/2024
Provenance du réseau au premier degré de Jimmie Harvey
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 30 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Jimmie Harvey via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| TG THERAPEUTICS, INC. | Pharmaceuticals: Major | Founder Chief Executive Officer Director/Board Member Director/Board Member | |
| KERYX BIOPHARMACEUTICALS | Pharmaceuticals: Major | Founder Chief Executive Officer Chairman Director/Board Member | |
| GENTIUM S.P.A. (ADR) | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director of Finance/CFO | |
Paramount BioCapital, Inc.
 Paramount BioCapital, Inc. Investment ManagersFinance Paramount BioCapital, Inc. is an alternative investment manager. The private company is based in New York, NY and has subsidiaries in the United States. | Investment Managers | Chief Executive Officer President Private Equity Investor | |
| University of Pennsylvania | College/University | Graduate Degree Undergraduate Degree | |
| Union College (New York) | College/University | Undergraduate Degree Undergraduate Degree | |
| University of Florida | College/University | Graduate Degree Undergraduate Degree | |
| University of Maryland | College/University | Undergraduate Degree | |
American Diabetes Association
 American Diabetes Association Miscellaneous Commercial ServicesCommercial Services American Diabetes Association provides diabetes related medical services. It funds research, publishes scientific findings, provides information and other services to people with diabetes, their families, health professionals and the public. The company was founded in 1940 and is headquartered in Alexandria, VA. | Miscellaneous Commercial Services | Director/Board Member | |
J&J Maintenance, Inc.
 J&J Maintenance, Inc. Miscellaneous Commercial ServicesCommercial Services J&J Maintenance, Inc. engages in providing operations and maintenance services. It offers base operations and logistics, construction management, environmental services, and operations and maintenance services. The company was founded by Johnny L. Voudouris in 1970 and is headquartered in Austin, TX. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
Johnson & Johnson Pharmaceutical Research & Development LLC
 Johnson & Johnson Pharmaceutical Research & Development LLC Miscellaneous Commercial ServicesCommercial Services Johnson & Johnson Pharmaceutical Research & Development LLC provides research and development support services. It offers drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. The company is headquartered in Raritan, NJ. | Miscellaneous Commercial Services | Chairman | |
| CHAMPIONS ONCOLOGY, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Director of Finance/CFO | |
Joslin Diabetes Center, Inc.
 Joslin Diabetes Center, Inc. Pharmaceuticals: MajorHealth Technology Joslin Diabetes Center, Inc. is a non-profit organization, which engages in the development of pharmaceuticals for diabetes. It provides adult care, pediatric care, eye care, and education programs and classes. The company was founded by Elliott P. Joslin in 1893 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Paramount BioSciences LLC
 Paramount BioSciences LLC Investment ManagersFinance Paramount BioSciences LLC (Paramount) is a venture capital firm founded in 1991. The firm is headquartered in New york. | Investment Managers | Chief Executive Officer President Private Equity Investor | |
Opus Point Partners Management LLC
 Opus Point Partners Management LLC Investment ManagersFinance Opus Point Partners Management LLC (OPPM) is a hedge fund manager headquartered in New York City. The firm was founded by Lindsay Rosenwald and Michael Weiss in 2009. They are owned by Opus Point Partners LLC, which is a subsidiary of Weiss & Co. LLC. OPPM manages investments that are dedicated to healthcare and life science. | Investment Managers | Chief Executive Officer Founder | |
| DIAMYD MEDICAL AB | Pharmaceuticals: Major | Director/Board Member | |
Patient-Centered Outcomes Research Institute
 Patient-Centered Outcomes Research Institute Miscellaneous Commercial ServicesCommercial Services Patient-Centered Outcomes Research Institute operates as a non-profit organization. It funds research that helps patients and care takers to make better decisions about their healthcare choices. The firm focuses on Comparative Clinical Effectiveness Research (CER), CER methods & infrastructure and related research studies. It funds to various private and public sectors including non-profit research organizations and profit research organizations, universities & colleges, hospitals and healthcare systems, laboratories & manufacturers, units of state, local and federal government. The company is headquartered in Washington, DC. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| IMMUNE PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| The Johns Hopkins University School of Medicine | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Biotechnology | Director/Board Member | |
| ORIGO ACQUISITION CORP | Financial Conglomerates | Chief Executive Officer Chairman Chief Operating Officer | |
| CHECKPOINT THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Chairman Chief Executive Officer Corporate Secretary | |
| AVENUE THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer Corporate Secretary Chief Executive Officer Director of Finance/CFO | |
Helocyte, Inc.
 Helocyte, Inc. Miscellaneous Commercial ServicesCommercial Services Helocyte, Inc. engages in the development and commercialization of immunotherapies for the prevention and treatment of cytomegalovirus or CMV (cancer and infectious disease). It focuses on developing PepVax, a HLA-restricted single antigen peptide vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant recipients and Triplex. The company was founded by Donald J. Diamond in 2015 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Founder Director/Board Member | |
| MUSTANG BIO, INC. | Pharmaceuticals: Major | Director/Board Member Chairman Corporate Secretary Director of Finance/CFO | |
3D Bio Holdings, Inc.
 3D Bio Holdings, Inc. Packaged SoftwareTechnology Services 3D Bio Holdings, Inc. develops term clinical applications. It focuses on whole tissue living implants. The company was founded by Hod Lipson, Larry Bonassar and Daniel L. Cohen and is headquartered in Brooklyn, NY. | Packaged Software | Chairman | |
Cyprium Therapeutics, Inc.
 Cyprium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Fortress Biotech, Inc., Cyprium Therapeutics, Inc. is an American New York-based company focused on developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders. The company was granted FDA breakthrough therapy, fast track, and rare pediatric disease designations, as well as FDA orphan drug designation for both Cutx-101 and AAV-ATP7A. The European Medicines Agency also granted orphan drug designation to Cyprium. In March 2017, Cyprium entered into a cooperative research and development agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development to advance the clinical development of Cutx-101 for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to Cutx-101 to Sentynl Therapeutics, Inc. Cyprium and NICHD also previously entered into a worldwide, exclusive license agreement to develop and commercialize AAV-ATP7A gene therapy, which is currently in pre-clinical development. The company was founded in 2017 by Michael Sean Weiss, Lindsay Allan Rosenwald, and Lung S. Yam, who has been the CEO since then. | Miscellaneous Commercial Services | Founder Founder | |
| Cellvation, Inc. | Chairman Director/Board Member | ||
| Rolf Lufts Stiftelse Foer Diabetesforskning | Director/Board Member | ||
Aadi Subsidiary, Inc.
 Aadi Subsidiary, Inc. BiotechnologyHealth Technology Aadi Subsidiary, Inc. engages in biopharmaceutical company. Its therapeutic programs include pulmonary arterial hypertension, pediatric solid tumors, solid tumors with mTOR activation and mitochondrial disease. The company was founded by Neil Desai and is headquartered in Pacific Palisades, CA. | Biotechnology | Director/Board Member | |
Caelum Biosciences, Inc.
 Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Mycrobiomics, Inc.
 Mycrobiomics, Inc. Miscellaneous Commercial ServicesCommercial Services Mycrobiomics, Inc. engages in research, education and coaching on the connection between health, microbiome and nutrition. The firm focuses on microbiome research commercialization opportunities, including oral, skin, and genitourinary tract microbiomes. The company was founded by George Cigale, Harlan F. Weisman, Sean Zinsley, Patrick J. Hanaway and William Daley Bonificio in 2015 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Founder | |
| TFF PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
| And-One Consulting LLC | Corporate Officer/Principal | ||
| Johnson & Johnson Medical Devices & Diagnostics Group | Chief Tech/Sci/R&D Officer | ||
Flame Biosciences LLC
 Flame Biosciences LLC Miscellaneous Commercial ServicesCommercial Services Flame Biosciences, Inc. operates as a biotechnology company. The firm offers research, development and commercialization of transformative therapies for cancer and other inflammatory conditions. The company was founded by Charles J. Fisher Jr., Patrick J. Scannon and Bob Stein and is headquartered in New York, NY. | Miscellaneous Commercial Services | Chief Executive Officer Corporate Officer/Principal | |
Baergic Bio, Inc.
 Baergic Bio, Inc. Pharmaceuticals: MajorHealth Technology Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
AnaCardio AB
 AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Pharmaceuticals: Major | Director/Board Member | |
| AADI BIOSCIENCE, INC. | Biotechnology | Director/Board Member | |
AI Proteins, Inc.
 AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| New York University School of Medicine | College/University | Corporate Officer/Principal Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 45 |
| Suède | 4 |
| Italie | 2 |
| Suisse | 2 |
Sectorielle
| Health Technology | 23 |
| Commercial Services | 10 |
| Finance | 7 |
| Consumer Services | 7 |
| Technology Services | 3 |
Opérationnelle
| Director/Board Member | 144 |
| Corporate Officer/Principal | 75 |
| Independent Dir/Board Member | 38 |
| Chief Executive Officer | 37 |
| Director of Finance/CFO | 37 |
Relations les plus connectées
| Insiders | |
|---|---|
| Eric Rowinsky | 36 |
| Bobby Sandage | 29 |
| Malcolm Hoenlein | 28 |
| J. Lobell | 27 |
| Michael Weiss | 25 |
| Lindsay Rosenwald | 23 |
| Karin Hehenberger | 21 |
| Harlan Weisman | 20 |
| Michael Rogers | 16 |
| Xiao Qin Lu | 15 |
| Gary Gemignani | 13 |
| Evan Renov | 12 |
| Kevin J. Horgan | 10 |
| Robyn Hunter | 10 |
| Glenn L. Cooper | 10 |
- Bourse
- Insiders
- Jimmie Harvey
- Connexions Sociétés
